SAN DIEGO, March 2, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the fourth quarter and year ended December 31, 2011 on Thursday, March 8, 2012 after the markets close. The announcement will be followed by a live webcast and conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (866) 804-6923 (domestic) or (857) 350-1669 (international), participant code 46352287. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials for which a New Drug Application has been submitted and reviewed by the FDA, and the FDA has agreed to a SPA for the Contrave outcomes trial. The Company’s other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.
Corporate Contacts: Orexigen | |
Orexigen | Media |
Jay Hagan | Denise Powell |
Chief Business Officer | WCG |
(858) 875-8673 | (510) 703-9491 |
SOURCE Orexigen Therapeutics, Inc.
